Anticoagulation is the cornerstone of stroke prevention in atrial fibrillation (AF). While warfarin has been a long-standing standard, limitations such as frequent INR monitoring, drug-food interactions, and increase bleeding risk have shifted practice toward direct oral anticoagulants (DOACs).